Health Trials

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

ConditionsNon-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal CarcinomaPancreatic AdenocarcinomaBreast CancerOther Solid TumorsOvarian CancerMyeloid Neoplasms (AML/MDS)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca

About this trial

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Eligibility criteria

Qualifiers

Subjects must be at least 18 years of age

NSCLC

Colorectal adenocarcinoma

HNSCC

Disqualifiers

Any another primary malignancy within the 3 years prior to enrollment

Known, active primary central nervous system (CNS) malignancy

History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.

History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.

Trial design

Treatments tested in this trial

  • NT-175

Treatment groups

45 Participants
are divided into 1 treatment group

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov